Core Viewpoint - The report details the usage and management of funds raised by Qipai Technology Co., Ltd. during its initial public offering, confirming that all funds have been utilized as promised in the prospectus and that the special account has been closed [1][2]. Fundraising Details - The total amount raised in the IPO was RMB 393,767,400, with a net amount of RMB 338,224,573.85 after deducting various fees [1]. - The funds were received on June 17, 2021, and the verification report was issued by Tianzhi International Accounting Firm on the same day [2]. Fund Usage - As of June 30, 2025, all raised funds have been fully utilized, and the special account has been closed [2][5]. - The funds were primarily used to increase the company's capital and expand related business operations, consistent with the commitments made in the prospectus [3][4]. Investment Projects - There were no changes to the actual investment projects funded by the raised capital, and the company has not transferred or replaced any investment projects [3][4]. - The company approved the use of RMB 80,665,400 to replace pre-invested funds and cover issuance costs, which was verified by Tianzhi International Accounting Firm [4]. Idle Funds Management - The company utilized up to RMB 25,000,000 of temporarily idle funds for cash management, with a rolling usage period of 12 months [4]. - As of June 30, 2025, the balance of idle funds used for purchasing financial products was RMB 0.00 [5]. Project Benefits - The benefits from the investment projects were calculated using the same methods as promised, with no projects reporting returns below 20% of the expected benefits [6]. - The R&D center expansion project could not be individually assessed for benefits but aimed to enhance overall R&D capabilities, indirectly improving company performance [6]. Comparison with Annual Reports - The actual usage of the raised funds has been consistent with the disclosures made in the company's periodic reports from 2021 to the present [6].

证券代码：688488 证券简称：艾迪药业 公告编号：2025-041 江苏艾迪药业集团股份有限公司 关于使用自有资金、银行承兑汇票等方式支付募投 项目所需资金并以募集资金等额置换的公告 经中国证券监督管理委员会出具《关于同意江苏艾迪药业股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1185 号）核准，公司向社会 公开发行人民币普通股 6,000 万股，发行价为每股人民币 13.99 元，募集资金总 额 为 人 民 币 839,400,000.00 元 ， 扣 除 承 销 费 用 和 保 荐 费 用 合 计 含 税 金 额 生 发 行 费 用 含 税 人 民 币 79,833,781.03 元 ， 包 含 可 抵 扣 增 值 税 进 项 税 额 上述募集资金已于 2020 年 7 月 13 日全部到位，容诚会计师事务所（特殊 普通合伙）对本次发行募集资金的到账情况进行了审验，并出具了容诚验字 [2020] 210Z0012 号《验资报告》。公司依照规定对上述募集资金进行专户存储 管理，并与保荐机构、募集资金专户监管银行签订了募集资金专户存储监管协 议。 二、 募集资金投资项目的基本情况 截止 ...

Core Viewpoint - The company intends to use part of its idle raised funds to temporarily supplement its working capital, with a limit of 50 million yuan, for a period not exceeding 12 months, ensuring compliance with regulatory requirements and maintaining the integrity of its investment projects [1][5][6]. Summary by Sections 1. Basic Situation of Raised Funds - The company has received approval from the China Securities Regulatory Commission for a non-public issuance of 88,008,000 shares at a price of 4.36 yuan per share, raising a total of 383,714,880 yuan, with a net amount of 376,615,860.47 yuan after deducting issuance costs [1][3]. 2. Previous Use of Idle Funds - The company previously used 50 million yuan of idle raised funds to supplement working capital, which was fully returned to the special account by August 14, 2025 [2]. 3. Investment Project Overview - The raised funds are allocated for several projects, including the acquisition of a 30% stake in Hezhong Building Materials, the construction of a PCCP production base in Henan, and a denitrification project for sintering machines [2][3][4]. 4. Current Plan for Temporary Use of Idle Funds - The company plans to use 50 million yuan of idle raised funds temporarily to meet operational needs while ensuring that the investment projects continue as planned [4][5]. 5. Board Review Process and Compliance - The board approved the use of idle funds without requiring shareholder meeting approval, confirming adherence to relevant regulations and ensuring no change in the intended use of the raised funds [5][6]. 6. Special Opinions and Sponsor's View - The sponsor, Zhongde Securities, supports the company's plan, confirming that it follows necessary legal procedures and does not harm the interests of the company or its shareholders [6].

广东科翔电子科技股份有限公司 根据中国证券监督管理委员会发布的《监管规则适用指引——发行类第 7 号》及相关规定，广东科翔电子科技股份有限公司（以下简称"本公司"）编制的 截至 2025 年 6 月 30 日《前次募集资金使用情况的专项报告》如下： 一、前次募集资金的募集及存放情况 （一）2020 年 11 月首次公开发行 A 股股票募集资金情况 经中国证券监督管理委员会"证监许可[2020]2393 号"文《关于同意广东科翔 电子科技股份有限公司首次公开发行股票注册的批复》同意注册，并经深圳证券 交易所同意，本公司由主承销商申港证券股份有限公司用网下询价配售与网上资 金申购定价发行相结合的方式发行人民币普通股(A 股)股票 4310 万股，发行价 格为每股 13.06 元。 本公司募集资金总额为 562,886,000.00 元，扣除公开发行股票发生的费用 况：扣除承销费用 39,826,839.62 元后实际资金到账 523,059,160.38 元，差额 本公司对募集资金采取了专户存储管理，前述募集资金已于 2020 年 11 月 2 日由主承销商申港证券汇入公司募集资金监管账户。公司 4 个募集资金专 ...

Core Points - The board of directors of Wangsu Technology Co., Ltd. held its 27th meeting on August 14, 2025, to review and approve several key proposals related to the company's financial performance and operational activities [1][2]. Financial Performance - The company reported a total operating income of 786.13 million yuan, representing a year-on-year increase of 7.71% [1]. - The net profit attributable to shareholders of the listed company was 372.51 million yuan, showing a year-on-year growth of 25.33% [1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 261.40 million yuan, reflecting a year-on-year increase of 22.53% [1]. Board Resolutions - The board unanimously approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational results [2]. - A special report on the storage and use of raised funds for the first half of 2025 was also approved [2]. - The board agreed to provide guarantees for its wholly-owned subsidiary, Shanghai Yunshu Technology Co., Ltd., for a loan application to Shanghai Bank, with a total guarantee amount not exceeding 30 million yuan [3]. - The company decided to apply for a credit limit of 30 million yuan from Ningbo Bank, with the credit being renewable within a one-year term [3].

东兴证券股份有限公司关于 青岛百洋医药股份有限公司 使用部分暂时闲置募集资金临时补充流动资金的核查意见 东兴证券股份有限公司（以下简称"东兴证券"或"保荐机构"）作为青岛 百洋医药股份有限公司（以下简称"百洋医药"或"公司"）2021 年度首次公开 发行股票、2023 年度向不特定对象发行可转换公司债券持续督导的保荐机构， 根据《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》 《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等规定，对百洋医药使用部分暂时闲置募集资金 临时补充流动资金的事项进行了核查，具体核查情况如下： 由于公司首次公开发行股票募集资金净额少于《青岛百洋医药股份有限公司 首次公开发行股票并在创业板上市招股说明书》中募投项目拟投入的募集资金金 额，根据实际募集资金净额，结合各募投项目的情况，公司对募集资金投资项目 拟投入募集资金金额进行调整。 根据市场变化及公司经营需要，为提高募集资金使用效率，公司终止"现代 物流配送中心建设项目"，该项目不再实施，并将上述项目的募集资金余额 时实际剩余募集资金金额为准）调整用于新项 ...

东方证券股份有限公司 关于技源集团股份有限公司 使用募集资金向全资子公司增资或借款 以实施募投项目的核查意见 东方证券股份有限公司（以下简称"保荐机构"）作为技源集团股份有限公司（简 称"技源集团"、"公司"）首次公开发行股票并在主板上市的保荐机构，根据《证 券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易所 股票上市规则》《上海证券交易所上市公司自律监管指引第1号——规范运作》等有 关法律法规和规范性文件的规定，对技源集团使用募集资金向全资子公司增资或 借款以实施募投项目的事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意技源集团股份有限公司首次公开发行 股票注册的批复》 （证监许可〔2025〕799号）同意注册，并经上海证券交易所同 意，公司向社会公开发行人民币普通股（A股）5,001.00万股，发行价格为10.88 元/股，本次发行募集资金总额为54,410.88万元，扣除发行费用6,429.06万元（不 含增值税）后，募集资金净额为47,981.82万元。立信会计师事务所（特殊普通合 伙）对公司本次公开发行新股的资金到位情况进行了审验并出 ...

Core Viewpoint - The company has approved the use of raised funds to increase capital and provide loans to its wholly-owned subsidiary, Qidong Jiyuan, for the implementation of fundraising investment projects [1][7]. Fundraising Overview - The company raised a total of RMB 54,410.88 million from the public offering of 50.01 million shares at a price of RMB 10.88 per share, with a net amount of RMB 47,981.82 million after deducting issuance costs of RMB 6,429.06 million [1][2]. Fundraising Investment Projects - The funds will be allocated to the following projects: - Jiyuan Group Nutrition Health Raw Material Production Base Construction Project - Qidong Jiyuan Nutrition Health Food Production Line Expansion Project - The total investment for these projects is RMB 60,272.93 million, with the adjusted amount for fundraising being RMB 47,981.82 million [3][2]. Capital Increase or Loan Details - The company plans to use RMB 14,730.50 million and RMB 9,913.75 million for capital increase or loans to Qidong Jiyuan, which will be used exclusively for the aforementioned projects [3][7]. - The loan terms will be based on the actual needs of the projects, with repayment options available [3][6]. Subsidiary Information - Qidong Jiyuan is a wholly-owned subsidiary of the company, with a registered capital of RMB 21,264.774 million and a business scope that includes health food production and sales [4][5]. Financial Performance of Subsidiary - Recent financial data for Qidong Jiyuan shows: - Total assets: RMB 34,498.41 million (audited), RMB 35,114.03 million (unaudited) - Total liabilities: RMB 5,637.25 million (audited), RMB 5,445.63 million (unaudited) - Net assets: RMB 28,861.16 million (audited), RMB 29,668.41 million (unaudited) - Revenue: RMB 24,033.00 million (audited), RMB 5,883.90 million (unaudited) - Net profit: RMB 3,277.50 million (audited), RMB 807.24 million (unaudited) [6]. Impact on the Company - The use of raised funds for the subsidiary is aligned with the company's long-term planning and development strategy, ensuring the smooth implementation of the fundraising investment projects [5][7]. - The company maintains control over the subsidiary's operations during the loan period, which mitigates financial risks [5][6]. Fund Management - The raised funds will be managed in a dedicated account, with a four-party supervision agreement established to ensure compliance with relevant regulations and proper use of funds [6][7]. Review Procedures - The board of directors and the supervisory board have approved the use of funds for the capital increase or loans, confirming adherence to necessary approval processes and regulations [7][8].

Group 1 - The company has approved a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.40 RMB per 10 shares, totaling 19,200,000 RMB, without any stock bonus or capital reserve conversion [3][10][22] - The company reported a net profit attributable to shareholders of 32,884,781.52 RMB for the first half of 2025, with cumulative undistributed profits amounting to 307,929,235.21 RMB as of June 30, 2025 [32][34] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5][6] Group 2 - The company held its second board meeting on August 12, 2025, where all directors attended and unanimously approved the half-year report and profit distribution plan [8][9][19] - The company has implemented changes in accounting estimates to better reflect its financial status and operational results, particularly regarding expected credit losses on receivables [36][38][41] - The company has adhered to regulations regarding the management and use of raised funds, with a total of 901,422,251.75 RMB net raised funds as of March 16, 2022, and a remaining balance of 39,751.51 million RMB as of June 30, 2025 [50][51][56]

Core Viewpoint - The company, Jiangsu Sop Chemical Co., Ltd., is undergoing significant governance changes, including the cancellation of its supervisory board and plans for a private placement of A-shares to enhance its capital structure and operational capabilities [3][7][28]. Group 1: Company Overview - Jiangsu Sop Chemical Co., Ltd. is involved in the production and sales of acetic acid and its derivatives, as well as chlor-alkali chemical raw materials [28][29]. - The company has a strong production capacity in the acetic acid sector and has obtained technology from DuPont for acetic acid vinyl production, indicating its capability to expand into downstream products [29]. Group 2: Financial Data - The company plans to raise up to 150 million RMB through a private placement of A-shares, which is expected to improve its financial strength and profitability [24][28]. - The company reported a net profit contribution of 7,248.54 million RMB from its investment projects in 2024, with an additional 2,951.63 million RMB in the first half of 2025, totaling 10,200.17 million RMB [23]. Group 3: Governance Changes - The company has decided to abolish its supervisory board, transferring its responsibilities to the audit committee of the board of directors, which is expected to streamline governance [3][4][5]. - The amendments to the company's articles of association and related rules are aimed at enhancing governance structures in line with regulatory requirements [5][6]. Group 4: Investment Projects - The company is focusing on expanding its product line into acetic acid vinyl, which aligns with its existing business and is expected to enhance product value and market competitiveness [28][29]. - The investment in acetic acid vinyl is anticipated to leverage existing raw material procurement capabilities, thereby achieving cost reductions and ensuring stable supply [29].